Mesenchymal stromal stem cell therapy (Cyndacel-M) in a flowable dermal matrix (Excellagen) for chronic diabetic wounds.

Trial Profile

Mesenchymal stromal stem cell therapy (Cyndacel-M) in a flowable dermal matrix (Excellagen) for chronic diabetic wounds.

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2014

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Chronic wounds
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Orbsen Therapeutics; Taxus Cardium Pharmaceuticals Group
  • Most Recent Events

    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top